Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

3C-TFE

Add links
From Wikipedia, the free encyclopedia

3C-TFE
Clinical data
Other names4-(2,2,2-Trifluoroethoxy)-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-(2,2,2-trifluoroethoxy)amphetamine; 3C-F3EM; α-Methyltrifluoroescaline; 3C-Trifluoroescaline
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action15 hours[1]
Identifiers
  • 1-[3,5-dimethoxy-4-(2,2,2-trifluoroethoxy)phenyl]propan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H18F3NO3
Molar mass293.286 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C(=C1)OC)OCC(F)(F)F)OC)N
  • InChI=1S/C13H18F3NO3/c1-8(17)4-9-5-10(18-2)12(11(6-9)19-3)20-7-13(14,15)16/h5-6,8H,4,7,17H2,1-3H3
  • Key:UBMKSRMQBSOFBH-UHFFFAOYSA-N

3C-TFE, also known as 4-(2,2,2-trifluoroethoxy)-3,5-dimethoxyamphetamine or as α-methyltrifluoroescaline (3C-trifluoroescaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA; 3C-M).[1][2][3] It is a trifluorinated derivative of 3C-E.[1][2][3] The drug's dose is 30 mg and its duration is approximately 15 hours.[1] It shows weak but significant affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 1,825 nM and 1,659 nM, respectively).[1] 3C-TFE was first described in the scientific literature by Daniel Trachsel in 2002.[3][2][1] The pharmacology of a number of 3C drugs was studied in 2021, but 3C-TFE was not one of the included compounds.[4] It is a controlled substance in Canada as an analogue of amphetamine.[5]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 736–737. ISBN 978-3-03788-700-4. OCLC 858805226.
  2. 1 2 3 Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
  3. 1 2 3 Trachsel D (2002). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate". Helvetica Chimica Acta. 85 (9): 3019–3026. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4.
  4. ↑ Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021). "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology. 12 794254. doi:10.3389/fphar.2021.794254. PMC 8865417. PMID 35222010.
  5. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=3C-TFE&oldid=1365179215"